ClinicalTrials.Veeva

Menu

Two Supplemented Against Skin Reactivity

L

L'Oreal

Status and phase

Completed
Phase 3

Conditions

Evaluation of Intestinal Flora Composition
Assessment of Skin Moisturization Factors
Clinical Score
Skin Sensitivity
Trans-epidermal Water Loss
Assessment of Serum Immune-regulatory Cytokine

Treatments

Dietary Supplement: Lactobacillus paracasei NCC 2461 and Bifidobacterium longum NCC3001

Study type

Interventional

Funder types

Industry

Identifiers

NCT01368224
1040341

Details and patient eligibility

About

In recent decades, the incidence of subjects presenting reactive skin has considerably increased in industrialized countries. Probiotics are live microorganisms which, when ingested in sufficient amounts, have beneficial effects on human health. The mechanism underlying the effect of probiotics involves, in part, regulation of the composition and/or metabolic activity of the intestinal microbiota.. It is postulated that following interaction of probiotics with the intestinal epithelium, associated intestinal cells become activated and consequently mediators are released into the blood circulation. Mediators, activated intestinal epithelial cells and possibly bacterial fractions might reach the skin through the bloodstream where they potentially could exert effects.The objective of this study was to assess the effects of probiotics on reactive skin symptoms. The strain Lactobacillus paracasei NCC2461 was tested alone and in combination with the strain Bifidobacterium longum NCC3001 in a randomized, double-blind study. The two strains were selected for their immune-modulatory properties demonstrated in in vitro and other preclinical studies as well as in a pilot clinical trial.

Ninety-six women presenting reactive skin were randomized to 3 groups: placebo (n = 32), L. paracasei NCC2461 alone (n = 32) and L. paracasei NCC2461 + B. longum NCC3001 (n = 32). The supplements were administered by the oral route for 58 days (1010 CFU/day).

The objective of the clinical trial was to determine, in vivo, the effect of food supplements on reactive skin symptoms (as measured by skin sensitivity and the reconstruction of barrier function post-repeated tape stripping).

The secondary objectives were to determine the effect of the food supplements on leg skin dryness and facial skin roughness and the associated biochemical, immunological and microbiological factors.

Accordingly, the subjects' skin sensitivity was determined by the capsaicin test. The reconstruction of barrier function was determined by measuring the trans-epidermal water loss (TEWL) post-repeated stripping using a SERVOMED evaporimeter. A clinical score for skin dryness and roughness was assigned by a dermatologist. The subjects also assessed their leg and facial skin dryness themselves. Each analysis was conducted at the various time points.

In parallel, assessment of the skin moisturizing factors and serum inflammatory and immune-regulatory cytokines were performed. Finally, key components of the intestinal microbiota were analyzed.

Full description

The probiotics and particularly Lactobacillus paracasei and Bifidobacterium longum are of value with respect to the homeostasis of dry and sensitive skin.

An initial study (study report No. 1020813, DERMSCAN dated 2/10/2004) showed that the combination of L. paracasei NCC2461 (ST11) with Bifidobacterium lactis NCC2818 (Bb12) induced an improvement in certain parameters related to skin reactivity. However, the probiotics have not been tested separately.

It was thus considered important to conduct a clinical trial aiming at confirming and documenting the data generated by the previous study and, also determining the specific efficacy of L. paracasei NCC2461 (ST11) on reactive skin symptoms. The latter probiotic strain was selected on the basis of its proven immune-modulatory properties (scientific dossier ST11-Nestec Benyacoub and Gueniche. Scientific evidence supporting the use of Lactobacillus paracasei NCC2461 (ST11) for Innéov. Report 11.02.2005 and references 23, 24, 31-33). The strain was combined or not with a probiotic of the Bifidobacterium genus, particularly Bifidobacterium longum NCC3001. The data generated by various preclinical studies (NRC in-house studies) and clinical studies (public) show that this probiotic strain is able to modulate immune mechanisms and could interfere with inflammatory reactions.

Moreover, the probiotic combination concept enables providing potential benefit all along the gastrointestinal tract, inducing maintenance of an optimum intestinal flora.

Enrollment

96 patients

Sex

Female

Ages

18 to 35 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy subject.
  • Gender: female.
  • Subject aged more than 18 years and less than 35 years (inclusive)
  • Phototype: I to IV
  • Caucasian race.
  • For women of child-bearing potential, effective contraception for at least 12 weeks and maintained throughout the study and for 1 month after completion of the study.
  • Sensitive skin: (1) as per the subjective evaluation questionnaire in appendix 12.2. (with at least 1 positive response to one of the first 3 questions) and (2) responder to the capsaicin test at one of the 3 lowest concentrationsSubject known to have dry leg skin (clinical score of at least 2 as per the scale).
  • Subject known to have rough cheek skin (clinical score of at least 3 as per the scale).
  • Low consumers of fermented dairy products (less than 125 g/d) and agreeing not to eat fermented dairy products containing live bacteria (yogurt, cottage cheese, fermented dairy products, unpasteurized cheese, etc.) for the duration of the study.

Exclusion criteria

  • Post-menopausal woman.

  • Pregnant or breast-feeding woman or woman planning pregnancy during the study.

    --Volunteer with a skin disease in the test areas (particularly acne rosacea). Volunteer presenting a stable or progressive serious disease (investigator's assessment).

  • Immunocompromised subject.

  • Subject allergic to one of the constituents of the test products and, in particular, capsaicin or pepper.

  • Alcohol intake greater than 2 glasses of wine daily or 1 glass of liquor daily.

  • Smoker of more than 6 cigarettes/day.

  • Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment).

  • Subjects regularly practicing aquatic or nautical sports.

  • Subjects regularly attending a sauna.

  • Subject with cardiovascular or circulatory history.

  • Subject with a history of skin cancer or malignant melanoma.

  • Subject with a history of intestinal surgery.

  • Intake of antibiotics, corticosteroids, non-steroidal anti-inflammatories or immune-suppressants.

  • Subject practicing sports for more than 5 hours per week.

  • Subject having taken mineral or vitamin supplements in the 3 months preceding the study (investigator's assessment).

  • Lacto-ovo-vegetarian, vegetarian.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

96 participants in 3 patient groups, including a placebo group

Maltodextrin
Placebo Comparator group
Treatment:
Dietary Supplement: Lactobacillus paracasei NCC 2461 and Bifidobacterium longum NCC3001
Lactobacillus paracasei NCC 2461 (ST 11)
Experimental group
Description:
1x1010 CFU of Lactobacillus paracasei NCC 2461 (ST 11)
Treatment:
Dietary Supplement: Lactobacillus paracasei NCC 2461 and Bifidobacterium longum NCC3001
Lactobacillus paracasei+ Bifidobacterium longum
Experimental group
Description:
1x1010 CFU of Lactobacillus paracasei NCC 2461 (ST 11) + 1x1010 CFU of Bifidobacterium longum (NCC3001)
Treatment:
Dietary Supplement: Lactobacillus paracasei NCC 2461 and Bifidobacterium longum NCC3001

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems